Cost of medications for patients with ischemic heart disease in a rural family practice center.
نویسندگان
چکیده
BACKGROUND Cardiovascular disease is the leading cause of death, and multiple medications are often needed to control symptoms and risk factors. Little research has explored the cost of medications for a typical patient with chronic ischemic heart disease. We undertook a study to determine the cost of medications and how they are paid for by patients in one rural clinic. METHODS One hundred four patients met criteria for chronic ischemic heart disease. We obtained patient information, risk factors, and current medications using retrospective chart reviews. We then calculated usual and customary costs per month for each of the 355 cardiac and 214 noncardiac prescriptions. After we determined which patients qualified for third party reimbursement or the community health center medication discount program, we calculated the actual out-of-pocket cost to the patient for each prescription. RESULTS Average monthly medication costs were $104.77 for cardiac medications and $115.54 for noncardiac medications, for a total of $220.31. Patients were reimbursed for approximately 64 percent of the total medications costs, making average out-of-pocket medication costs $41.52 for cardiac medications and $36.86 for noncardiac medications, for a total of $78.38. Seventy-one percent of patients were reimbursed by their insurance company, 19 percent qualified for the medication discount program, and 10 percent had no assistance. Patient risk factors included positive family history of chronic ischemic heart disease (71 percent), hypertension (64 percent), history of smoking (61 percent), currently smoking (26 percent), diabetes (25 percent), and recently elevated cholesterol levels (67 percent of 76 patients). CONCLUSIONS Medication costs for patients with chronic ischemic heart disease are expensive and burdensome. Third party payers and the medication discount program relieved a considerable (64 percent) but inadequate amount of prescription costs. Multiple risk factors coexist with these medication costs. Patient behavior modification and an aggressive approach to risk reduction might reduce these costs.
منابع مشابه
The effect of the family-centered educational program on medication management in elderly patients with ischemic heart disease
Introduction: The elderly population is rising in Iran and other countries, and chronic diseases such as heart disease are prevalent among this population. People, especially in chronic diseases, depend on their families, and the family plays an important role in patient compliance with therapeutic and nutritional recommendations, and can be used to improve the quality of education for patients...
متن کاملThe relation between body mass index and prevalence of ischemic heart disease in type 2 diabetic patients
Background: The transition from communicable to non-communicable diseases has occurred over many years in all countries of the world, even in developing countries. Diabetes and its ischemic heart complication are among the most important second groupe diseases. In recent years, discussions about the role of obesity and weight gain have risen again as a risk factor for both diseases. Our objecti...
متن کاملCauses of readmission in ischemic heart disease patients
Introduction: Ischemic heart diseases are the most prevalent causes of diseases in hospitals and are the second cause of mortality in Iran. Treatment cost for most of these preventable causes of readmission is remarkably high. This study is designed to investigate the readmission causes of ischemic heart diseases in Bandar Abbas. Methods: In this descriptive study, during a 6 month period, al...
متن کاملThe Satisfaction of Ischemic Heart Disease Patients With Nursing Care in Emergency Department
Background: Emergency department congestion is among the major barriers to receiving nursing care for high-priority conditions, like ischemic heart disease. Therefore, it can affect patients’ satisfaction with the quality of care. This study aimed to investigate satisfaction with emergency care among patients with ischemic heart disease. Methods: This cross-sectional study was conducted on 600...
متن کاملGenetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease
Background: Clopidogrel is a standout amongst the most ordinarily recommended medications to avoid ischemic occasions taking after coronary disorder or stant position. However, impaired responses the therapy as well as resistance to the therapy have also been reported. Genetic variants play an important role in clopidogrel biotransformation of its active metabolite that may subsequently influen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of the American Board of Family Practice
دوره 12 3 شماره
صفحات -
تاریخ انتشار 1999